Virtus Investment Advisers’s Capricor Therapeutics CAPR Stock Holding History

Virtus Investment Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305K	Buy	12,682 +2,203	+21%	+$66.8K	0.07%	369
2026 Q1	$319K	Buy	10,479 +255	+2%	+$6.79K	0.09%	270
2025 Q4	$295K	Buy	10,224 +2,061	+25%	+$26.9K	0.08%	256
2025 Q3	$58.9K	Buy	8,163 +1,417	+21%	+$10.4K	0.02%	437
2025 Q2	$67K	Sell	6,746 -4,702	-41%	-$49.7K	0.02%	436
2025 Q1	$109K	Buy	+11,448	New	+$159K	0.03%	409

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtus Investment Advisers's CAPR Position: Q2 2026 in Review

Virtus Investment Advisers increased its Capricor Therapeutics (CAPR) stake by 21% in Q2 2026, buying an estimated $66.8K and bringing the position to 12,682 shares worth $305K. The position accounts for 0.07% of the portfolio, ranked #369.

Virtus Investment Advisers first reported a position in CAPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $319K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Virtus Investment Advisers held 12,682 shares of Capricor Therapeutics worth $305K as of Q2 2026.
Virtus Investment Advisers bought 2,203 Capricor Therapeutics shares in Q2 2026, an estimated $66.8K.
Capricor Therapeutics made up 0.07% of Virtus Investment Advisers's portfolio in Q2 2026, its #369 holding.
Virtus Investment Advisers first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 6 quarters since.
Virtus Investment Advisers's Capricor Therapeutics position peaked at $319K in Q1 2026.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.